Abstract:Historically, our understanding of the cytotoxicity of radiation has centred on tumour cell-autonomous mechanisms of cell death. Here, tumour cell death occurs when a threshold number of radiation-induced non-reparable double-stranded DNA breaks is exceeded. However, in recent years, the importance of immune mechanisms of cell death has been increasingly recognised, as well as the impact of radiotherapy on non-malignant cellular components of the tumour microenvironment. Conserved antiviral pathways that detect foreign nucleic acid in the cytosol and drive downstream interferon (IFN) responses via the cyclic guanosine monophosphate-adenosine monophosphate synthase/stimulator of IFN genes (cGAS/STING) pathway are key components of the immune response to radiation-induced DNA damage. In preclinical models, acute induction of a type 1 IFN response is important for both direct and abscopal tumour responses to radiation. Inhibitors of the DNA damage response show promise in augmenting this inflammatory IFN response. However, a substantial proportion of tumours show chronic IFN signalling prior to radiotherapy, which paradoxically drives immunosuppression. This chronic IFN signalling leads to treatment resistance, and heterotypic interactions between stromal fibroblasts and tumour cells contribute to an aggressive tumour phenotype. The effect of radiotherapy on myeloid cell populations, particularly tumour-associated macrophages, has an additional impact on the immune tumour microenvironment. It is not yet clear how the above preclinical findings translate into a human context. Human tumours show greater intratumoural genomic heterogeneity and more variable levels of chromosomal instability than experimental murine models. High-quality translational studies of immunological changes occurring during radiotherapy that incorporate intrinsic tumour biology will enable a better understanding of the immunological consequences of radiation-induced DNA damage in patients. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy

Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches

Targeting Innate Immunity in Cancer Therapy

Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness

Targeting the Innate Immune System with Nanoparticles for Cancer Immunotherapy

Immune targets in the tumor microenvironment treated by radiotherapy

Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy

Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality

From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy

Innate Immunity in Cancer Biology and Therapy

Exploiting innate immunity for cancer immunotherapy

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

The Intersection of Radiotherapy and Immunotherapy: Mechanisms and Clinical Implications.

Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization

Radiation-induced Adaptive Response: New Potential for Cancer Treatment

Radiation-induced Tumor Immune Microenvironments and Potential Targets for Combination Therapy

Target tumor microenvironment by innate T cells

The immunological consequences of radiation-induced DNA damage

Harnessing innate immune pathways for therapeutic advancement in cancer

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy